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summARy – The aim was to determine the validity of the international normalized ratio 
(inR) and prothrombin time (pt) as a monitor for warfarin therapy in patients with lupus anticoa-
gulants and recurrent thrombosis, and to investigate alternative approaches to monitoring warfarin 
therapy and new treatment options in these patients. A case is described of a 63-year-old female 
with antiphospholipid syndrome and recurrent venous thrombosis despite optimal adjusted warfarin 
therapy. in patients with lupus anticoagulants, the inRs obtained while receiving warfarin vary and 
often overestimate the extent of anticoagulation, while pt without receiving warfarin is often pro-
longed. in conclusion, lupus anticoagulants can influence pt and lead to inR that does not accura-
tely reflect the true level of anticoagulation. optimizing of (warfarin) oral anticoagulation therapy 
could be achieved by individual monitoring of anticoagulation effect with a test that is insensitive to 
lupus anticoagulants (chromogenic factor X assay). emerging oral anticoagulants, direct thrombin 
inhibitors and direct factor Xa inhibitors, such as dabigatran and rivaroxaban, with a predictable 
anticoagulant response and little potential for food or drug interactions, have been designed to be 
administered in fixed doses without coagulation monitoring and could be the treatment choice for 
these patients.
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Introduction
The term antiphospholipid syndrome (Aps) or 
hughes syndrome is used to link a variety of throm-
boembolic events to antibodies against specific pro-
teins and lipoproteins involved in blood coagulation1. 
Thrombotic events are reported in approximately 30% 
of patients with antiphospholipid antibodies with an 
overall incidence of 2.5% patients/year2,3. deep vein 
thrombosis of the legs and/or pulmonary embolism 
account for about two thirds of thrombotic events, and 
cerebral arterial thrombosis is the most common arte-
rial complication. several hypotheses have emerged to 
explain the correlation between antiphospholipid an-
tibodies and thrombosis: 1) activation of the procoag-
ulant activity of endothelial cells by antiphospholipid 
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antibody binding to ß2-glycoprotein on the resting 
endothelial cells, nucleus activation, and up-regula-
tion of adhesion molecules, secretion of cytokines, 
expression of tissue factor, and metabolism of pros-
tacyclins4; 2) oxidant-mediated injury of vascular en-
dothelium; antiphospholipid antibodies may promote 
atherogenesis by acting against oxidized low-density 
lipoprotein (ldl). in this potential mechanism, the 
antibodies bind to ß2-glycoprotein i, which is also 
known as apolipoprotein h and is present in oxidized 
ldl. uptake of oxidized ldl by macrophages leads 
to macrophage activation, damage to endothelial cells, 
and subsequent promotion of thrombosis5; 3) interfer-
ence with phospholipid-binding proteins involved in 
the regulation of coagulation; ß2-glycoprotein i plays 
a regulatory role within the coagulation pathways and 
may act as a natural anticoagulant. The binding of 
antiphospholipid antibodies to ß2-glycoprotein i may 
inhibit its anticoagulant activity. other phospholip-
id-binding proteins, such as tissue factor-factor viia 
complex and prekallikrein, which are components of 
the extrinsic and intrinsic coagulation pathways, re-
spectively, may be targets of antiphospholipid anti-
bodies6; 4) by the effect on platelets, antiphospholipid 
antibodies may promote their activation, facilitating 
adherence to the endothelium. one model suggests 
that the binding of antibodies to ß2-glycoprotein i in-
creases platelet adhesion to collagen, as well as plate-
let aggregation7; 5) by impairing the fv and fviii 
degradation induced by protein C (pC); ‘second hit’ 
hypothesis, where antiphospholipid antibodies could 
inhibit enzymatic function of pC and ps complex8. 
The exact mechanism of hypercoagulability in these 
patients remains unclear. however, in patients with 
pre-existing antibody disease, acute conditions that 
exacerbate the inflammatory response induce hyper-
coagulability and risk of thrombosis9. prolonged an-
ticoagulation is the treatment of choice for patients 
with thrombosis and antiphospholipid syndrome. 
warfarin has numerous limitations, including slow 
onset and offset of action, a narrow therapeutic range, 
and a metabolism that is affected by diet, drugs, and 
genetic polymorphisms. because of its unpredictable 
dose response, warfarin requires careful coagulation 
monitoring to ensure that the therapeutic anticoagu-
lant effect is achieved. however, there is still debate 
about the optimal intensity of anticoagulation10. The 
other aspect relates to the monitoring of oral antico-
agulation, which is still an unsolved issue in patients 
with antiphospholipid antibodies. laboratory control 
of oral anticoagulant therapy by use of prothrombin 
time and international normalized ratio (pt-inR) 
might be inappropriate in lupus anticoagulant-positive 
patients because the inR may not reflect the true level 
of anticoagulation11. 
Case Report
A 63-year-old female patient with a 15-year his-
tory of recurrent venous thromboembolism was ad-
mitted to the hospital because of clinical and ultra-
sound verified acute deep ileofemoral thrombosis 
of the right leg. she had no recent immobilization, 
trauma or surgery. during the last seven years, she 
was taking warfarin with inR values of 2.2-3.5 in last 
three months. The inR range was 2.5-5.0. After war-
farin withdrawal and administration of fractionated 
heparin (dalteparin) and methylprednisolone (1 mg/
kg i.v.), prothrombin activity remained continuously 
low, about 25%. other findings: positive lupus antico-
agulant test 3.30 (normal range <1.3), high anticardi-
olipin antibody titer, igg type >120 u/ml units and 
igm 17.8 u/ml units, low fibrinogen levels, increased 
fibrinogen degradation products and d-dimers. mild 
thrombocytopenia (56x109/l) and anemia (hb 108 
g/l) with positive direct antiglobulin test (dAt) were 
recorded in peripheral blood, and platelet polymor-
phism with normal myelopoiesis and erythropoiesis in 
bone marrow aspirate. electrocardiogram, chest radi-
ography and serum testing for cancer markers (CeA, 
CA 19-9, CA 125, Ca 15-3) were normal. 
After 8-day heparin therapy and reduction of local 
edema and pain, warfarin was reinstituted in a dose of 
3 mg/day and inR 2.5 was recorded. in two weeks of 
discharge, the patient developed cellulitis of the right 
calf with thrombophlebitis of superficial veins. syn-
chronous therapy with a beta-lactam antibiotic, war-
farin and low-dose fractionated heparin resolved the 
inflammation and thrombophlebitis 
in her past history, 15 years before, venous throm-
bosis was diagnosed and continuous oral anticoagula-
tion prescribed. her family history was contributory 
for venous thrombosis. ten years before, she had re-
lapsing deep vein thrombosis on the contralateral calf 
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complicated with pulmonary embolism, and seven 
years before she had venous rethrombosis despite con-
tinuous warfarin therapy. until 7 years before, she had 
a high titer of anticardiolipin antibodies of igg type 
(98 u/ml units, normal <10 u/ml units) and igm 
(30 u/ml units, normal <7 u/ml units). The diag-
nosis of antiphospholipid syndrome was established. 
The complement C3 and C4 activity was normal and 
platelet count decreased (72x109/l). molecular assess-
ments of the genes for fv leiden and prothrombin 
g20210A mutation were normal. At the same time, 
signs of renal failure (creatinine 155 mmol/l, potas-
sium 5.6 meq/l, creatinine clearance 48 ml/min) 
and atherosclerosis of leg arteries were noticed. Ab-
dominal ultrasonography revealed glomerulosclerosis 
of the right kidney and afunction of the left one, with 
occlusion of the left renal artery. igg monoclonal 
gammopathy with normal results of bone marrow as-
piration and normal skeletal radiography fulfilled the 
criteria of monoclonal gammopathy of undetermined 
significance.
Discussion
The case presented illustrates recurrent venous 
thrombosis in warfarin treated antiphospholipid syn-
drome. Three retrospective studies report that recur-
rent thrombosis occurred in 52%, 69%, and 51.8% of 
patients with antiphospholipid syndrome during the 
follow up period (5, 6 and 6.4 years, respectively), re-
gardless of antithrombotic strategy12-14. prospectively, 
schulman et al. demonstrated that in patients with an 
initial venous thromboembolic event who completed 
6 months of oral anticoagulant therapy the risk of 
recurrent thrombosis was 29% in patients with anti-
cardiolipin antibodies as compared to 14% in those 
without these antibodies (P=0.0013)15. The high con-
centration of igg and igm anticardiolipin antibodies 
in our patient could aggravate hypercoagulation state 
and cause recurrent venous thromboses, as well accel-
erate atherosclerosis of leg arteries. despite continu-
ous oral anticoagulation of medium to high intensity 
and ‘optimal warfarin dosage’, she developed five epi-
sodes of recurrent venous thromboembolism in a 15-
year period. 
Relatively few data are available on those patients 
that sustain a recurrent thromboembolic event in the 
setting of therapeutic oral anticoagulation. optimal 
therapy for patients with lupus anticoagulants who 
have sustained a thromboembolic event is controver-
sial. A variety of treatment strategies have been used, 
including addition of antiplatelet agents to higher-
intensity oral anticoagulation, conversion from oral 
anticoagulants to therapeutic dose low-molecular 
weight heparin, and addition of immunomodulatory 
strategies. immunomodulatory therapies that have 
been anecdotally used in patients with antiphospho-
lipid syndrome include steroids, cyclophosphamide, 
and rituximab, but these are generally used in com-
bination with an aggressive antithrombotic strat-
egy. Rosove and brewer recommend that the inR in 
these patients should be maintained at 2.6 or greater 
because a higher recurrence rate was seen in patients 
whose inR was less than 2.612. for the same reason, 
Khamashita et al. recommend high-intensity antico-
agulation with inR of 3.0 or greater for patients with 
antiphospholipid antibodies and thrombotic events16. 
in contrast, ginsberg et al. suggest that an inR of 
2.0 to 3.0 is sufficient because they saw no recurrent 
thrombosis during conventional-intensity warfarin 
therapy17. however, none of these studies consid-
ered the observation that patients with lupus antico-
agulants may have a spontaneous, non-medication 
induced pt prolongation18. our patient had positive 
lupus anticoagulants with in vitro prolongation of ac-
tivated partial thromboplastin time (Aptt) and pt. 
lupus anticoagulants are antiphospholipid antibodies 
that interfere with phospholipid-dependent coagula-
tion reactions in vitro. They are frequently associated 
with prolonged Aptt or dilute Russell viper venom 
time19. Antiphospholipid antibodies have been shown 
to interfere in vitro with the activation of factor X by 
the intrinsic factor-f X complex and of prothrombin 
by the prothrombinase complex, being the mechanism 
of therapy resistant hypercoagulation state in our pa-
tient20. Although it has been stated that prolonged pt 
is ‘uncommon’ in patients with lupus anticoagulants, 
horellou et al. describe 57 patients with lupus anti-
coagulants, 31 of them having prolonged pt (53%). 
because some patients with lupus anticoagulants have 
a prolonged pt as the result of antibody-mediated de-
crease in f ii activity, horellou et al. measured these 
levels and found them to be normal in 30 of these pa-
tients21. fleck et al. report that pt was prolonged by 
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more than 2 seconds in 12 of 42 (28.6%) patients with 
lupus anticoagulants and normal factor ii activity22. 
in some patients, particularly those with prolonged 
baseline pt, the inR will not be reliable and such sit-
uation was in our patient in the last 15 years. optimal 
therapeutic management for these patients would be 
established by the prothrombin-proconvertin time or 
chromogenic factor X assay. we could not obtain di-
agnostic kit for these assays despite intensive efforts 
invested in search for it. in other patients, the inR 
obtained by using thromboplastin that is relatively 
insensitive to lupus anticoagulants may be sufficient. 
however, a normal baseline pt does not guaran-
tee that the inR will be accurate in this patient. As 
neither chromogenic factor X nor prothrombin-pro-
convertin time assay is widely available to many clini-
cians, alternative approaches to anticoagulant therapy 
in these patients should be identified. 
other authors claim that warfarin therapy often 
fails in patients with antiphospholipid antibodies and 
venous thromboembolic disease and that these pa-
tients “are best managed by use of long-term heparin 
therapy”23. Although low-molecular-weight heparins 
may increase the risk of osteoporosis and eliminate the 
need for monitoring, the cost of these medications cur-
rently precludes their long-term use in most patients24. 
fondaparinux is a new subcutaneous anticoagulant 
that indirectly inhibits factor Xa. it has been shown 
to be safe and effective in the acute treatment of deep 
vein thrombosis and pulmonary emboli, and also in 
venous thrombosis prevention in patients undergoing 
hip and knee surgery25. As with the new antiplatelet 
agents, no controlled studies exist on the long-term 
use of heparin for secondary thrombosis prevention 
in antiphospholipid syndrome, although heparin has 
been used empirically in warfarin-resistant antiphos-
pholipid syndrome patients. 
A host of potential new oral anticoagulant agents 
(fig. 1), which could become much-needed replace-
ments for warfarin and could also be used as an alter-
native to heparins or other antithrombin agents, are 
making good progress in development, with at least 
two agents now in phase iii trials. however, experts 
are cautious following the fall from glory of the first 
such agent to be developed, ximelagatran, which ac-
tually reached the market in europe but was swiftly 
withdrawn because of liver toxicity. nevertheless, as 
there are so many new compounds in development, 
researchers are optimistic that this time at least one or 
two will succeed and provide millions of patients who 
are or should be taking warfarin with a much more 
user-friendly treatment. 
The new agents furthest on the development are 
the factor iia inhibitor dabigatran and the factor Xa 
inhibitor rivaroxaban. These agents are initially being 
developed for the prevention of thrombosis in ortho-
pedic surgery patients, but both dabigatran and rivar-
oxaban are also now starting late-stage trials for the 
prevention of stroke in atrial fibrillation patients (as 
a replacement for warfarin) and in the treatment of 
acute coronary syndromes. 
Rivaroxaban is an anticoagulant in a novel class 
that exerts its effect by directly binding to the ac-
tive site of factor Xa. Activated factor X serves as the 
link between the extrinsic and intrinsic pathways of 
the coagulation cascade, and serves as the rate lim-
iting step in the production of thrombin. its action 
results in a dose-dependent increase in both pt and 
Aptt26. Rivaroxaban appears to be well absorbed 
following oral administration, with a bioavailability 
Oral factor Xa inhibitors (rivaroxaban, apixaban) bind di-
rectly to factor Xa and prevent thrombin generation. Dab-
igatran etexilate, an orally active direct thrombin inhibitor, 
undergoes metabolic activation to dabigatran, which binds to 
the active site of thrombin (factor IIa) and blocks its capac-
ity to convert fibrinogen to fibrin, to activate platelets, and 
to amplify its own generation by activating factors V, VIII, 
and XI. By blocking the active site of thrombin, dabigatran 
also blocks the activation of protein C and thrombinactivat-
able fibrinolysis inhibitor by the thrombin/thrombomodulin 
complex.
Fig. 1. Targets of new anticoagulant drugs. 
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of 60% to 80%, achieving maximal factor Xa inhi-
bition within 3 hours. half-life is approximately 6 
to 7 hours, but may be extended, requiring dosage 
adjustment, in elderly patients and those with renal 
insufficiency27. increases in dosage were associated 
with increased effect on coagulation studies and with 
increased bleeding, but not necessarily increased ef-
ficacy. based on these, phase iii studies specific to 
venous thromboembolism prophylaxis used fixed oral 
doses of rivaroxaban 10 mg given once daily and did 
not use monitoring of coagulation studies. Thus far, 
studies comparing rivaroxaban to enoxaparin in the 
setting of venous thromboembolism prophylaxis have 
shown improved efficacy with similar safety after ma-
jor orthopedic surgery (ReCoRd study group)28-30. 
This agent is also under investigation for treatment 
and secondary prevention of venous thromboembo-
lism (einstein), prevention of stroke in patients 
with atrial fibrillation (RoCKet-Af) and medical 
management of acute coronary syndromes (AtlAs 
ACs timi 51). After 2008, rivaroxaban is currently 
approved in the uK, Canada and europe for preven-
tion of venous thromboembolism in adult patients 
undergoing elective hip or knee replacement surgery. 
in the usA, rivaroxaban approval is pending due to 
the food and drug Administration (fdA) concerns 
about the risks of bleeding (ReCoRd study: “any 
major bleeding” event occurring in 0.39% of the ri-
varoxaban group and 0.21% of the enoxaparin group) 
and substantial risk of liver injury/hepatotoxicity. 
of the new oral anticoagulants, dabigatran etexi-
late is a drug in the most advanced stage of devel-
opment. dabigatran etexilate is an oral prodrug with 
rapid onset of action, resulting in anticoagulant effects 
within 2 hours of administration. The pharmacoki-
netic and pharmacodynamic profiles are predictable 
with dose-proportional increase in the concentration 
curves, with steady state achieved in 3 days. dabiga-
tran is predominately eliminated via the kidney (up 
to 80%), and does not undergo hepatic metabolism, 
nor were clinically significant drug-drug interactions 
observed when tested with atorvastatin, diclofenac, 
or digoxin. small differences in drug clearance were 
observed in women and the elderly, and thought to 
be related to change in renal function31. The preven-
tion of venous Thromboembolism after total hip 
Replacement (Re-novAte) trial compared dab-
igatran 150 mg or 220 mg daily to enoxaparin 40 mg 
subcutaneous daily in 3494 patients for prevention of 
venous thromboembolism or all-cause mortality. This 
trial was the first to use dabigatran for an extended 
period of time, with treatment continuing to a me-
dian of 33 days postoperatively. dabigatran again 
showed benefit compared to enoxaparin (absolute 
risk reduction by 1.9% and 0.7%); however, it did not 
demonstrate an increase in bleeding. two fatal bleeds 
occurred during this trial, both in patients receiving 
dabigatran. study authors conclude that dabigatran 
was not inferior to enoxaparin in the prevention of ve-
nous thromboembolism. The Thromboembolism pre-
vention After Knee surgery (Re-model) trial and 
dabigatran versus enoxaparin in preventing venous 
Thromboembolism following total Knee Arthro-
plasty (Re-mobiliZe) trial were similar in design 
to Re-novAte, with the exception of the patient 
population evaluated. The Re-model trial used 
lower dose enoxaparin (40 mg daily s.c.), whereas the 
Re-mobiliZe trial used enoxaparin 30 mg bid s.c. 
bid as active control. Re-model was able to demon-
strate noninferiority of dabigatran at both doses (150 
mg and 220 mg daily), with the composite of venous 
thromboembolism and all-cause mortality occurring 
in 40.5%, 36.4%, and 37.7%, with each regimen of 
dabigatran and enoxaparin respectively. bleeding 
rates were low across all groups during the treatment 
period of 6 to 10 days and throughout 3-month follow 
up. All arms had higher than expected rates of ve-
nous thromboembolism. however, when compared to 
enoxaparin 30 mg s.c. twice daily, dabigatran did not 
reach the pre-specified noninferiority outcome for the 
composite of deep vein thrombosis, pe, and all-cause 
mortality. The primary endpoint occurred in 33.7% 
with dabigatran 150 mg daily, 31.1% with dabigatran 
220 mg daily, and 25.3% with enoxaparin 30 mg twice 
daily during the 12- to 15-day treatment. These trials 
indicate the need for a larger trial to support the use 
of dabigatran over a regimen of twice daily enoxaparin 
following total knee replacement32.
The efficacy of dabigatran in stroke prevention in 
18,113 patients with atrial fibrillation was addressed 
by the Rely noninferiority trial. in a blinded fash-
ion, the fixed doses of dabigatran 110 mg or 150 mg 
were administered twice daily and, in an unblinded 
fashion, adjusted-dose warfarin. The median follow 
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up duration was 2.0 years. The primary outcome was 
stroke or systemic embolism. Resulting rates of prima-
ry outcome were 1.69% per year in the warfarin group, 
as compared with 1.53% per year in the group that 
received 110 mg of dabigatran (P<0.001 for noninfe-
riority), and 1.11% per year in the group that received 
150 mg of dabigatran ( P<0.001 for superiority). The 
rate of major bleeding was 3.36% per year in the war-
farin group, as compared with 2.71% per year in the 
group receiving 110 mg of dabigatran (P=0.003), but 
in the group receiving 150 mg of dabigatran the inci-
dence of bleeding was higher, 3.11% (P=0.31). There 
was also a significantly higher rate of major gastroin-
testinal bleeding with dabigatran at the 150-mg dose 
than with warfarin. The rate of hemorrhagic stroke 
was 0.38% per year in the warfarin group, as com-
pared with 0.12% per year with 110 mg of dabigatran 
(P<0.001) and 0.10% per year with 150 mg of dabiga-
tran (P<0.001). The mortality rate was 4.13% per year 
in the warfarin group, as compared with 3.75% per 
year with 110 mg of dabigatran (P=0.13) and 3.64% 
per year with 150 mg of dabigatran (P=0.051). until 
now, this trial had the longest follow up of dabigatran 
administration and the only adverse effect that was 
significantly more common with dabigatran than with 
warfarin was dyspepsia. elevation in serum aspartate 
aminotransferase or alanine aminotransferase level to 
more than 3-fold upper limit of the normal range was 
not more frequent with dabigatran at either dose than 
with warfarin33. 
The efficacy and safety of dabigatran in the preven-
tion of venous thrombosis recurrence was tested in the 
Re-CoveR randomized, double-blind noninferior-
ity trial. oral dabigatran administered at a dose of 150 
mg twice daily was compared with warfarin that was 
dose-adjusted to achieve inR of 2.0 to 3.0 in 1274 
patients with acute venous thromboembolism that 
were initially administered parenteral anticoagula-
tion therapy for a median of 9 days. The primary out-
come was 6-month incidence of recurrent symptom-
atic, objectively confirmed venous thromboembolism 
and related deaths. safety endpoints included bleed-
ing events, acute coronary syndromes, other adverse 
events, and results of liver function tests. Recurrent 
venous thromboembolism was recorded in 30 (2.4%) 
of 1274 patients randomly assigned to receive dabiga-
tran as compared with 27 (2.1%) of 1265 patients ran-
domly assigned to warfarin (P<0.001 for noninferior-
ity). major bleeding episodes occurred in 20 (1.6%) 
patients assigned to dabigatran and 24 (1.9%) patients 
assigned to warfarin; and episodes of any bleeding 
were observed in 205 (16.1%) patients assigned to 
dabigatran and 277 patients assigned to warfarin. The 
numbers of deaths, acute coronary syndromes and 
abnormal liver function tests were similar in the two 
groups. Adverse events leading to discontinuation of 
the study drug occurred in 9.0% of patients assigned 
to dabigatran and 6.8% of patients assigned to warfa-
rin (P=0.05), therefore the safety profile of dabigatran 
is similar to that of warfarin34. 
despite these encouraging new therapeutic ap-
proaches, warfarin is the gold standard for the reduc-
tion of hypercoagulability status. much of the success 
of rivaroxaban and dabigatran will depend on how they 
can penetrate the existing market and then expand their 
current scope. however, there are a number of factors 
that could constrain their uptake. Current therapies are 
well entrenched in physicians’ minds and benefit from 
large amounts of clinical data; overcoming the physi-
cians’ familiarity will be difficult. warfarin has been in 
use for more than half a century.
All anti-clotting agents carry a risk of unwanted 
bleeding events, and the new oral anticoagulants are 
no exception. Although antidotes for these drugs are 
in preclinical development, they will not be available 
in short term. prices could be another significant ob-
stacle, particularly at the time of drastic cost-contain-
ment strategies in healthcare systems, as some payers 
will go for the less expensive option. Another factor in 
the market is the expected approval of biosimilar ver-
sions of enoxaparin, which will lead to greater interest 
in this field and potentially lower prices. Rivaroxaban 
and dabigatran also face some serious competition 
from other competitor drugs now in development.
Apixaban, an orally active factor X inhibitor, was 
tested in the AdvAnCe-2 study. patients undergo-
ing elective unilateral or bilateral total knee replace-
ment were randomized to receive oral apixaban 2.5 
mg twice daily (n=1528) or subcutaneous enoxaparin 
40 mg once daily (n=1529). venous thromboembolism 
was reported in 147 (15%) of 976 apixaban patients 
and 243 (24%) of 997 enoxaparin patients (relative 
risk 0.62 [95% Ci 0.51-0.74]; P<0.0001; absolute risk 
reduction 9.3% [5.8-12.7]). major or clinically relevant 
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non-major bleeding occurred in 53 (4%) of 1501 pa-
tients receiving apixaban and 72 (5%) of 1508 patients 
treated with enoxaparin (P=0.09)35. 
Another novel oral factor Xa inhibitor under de-
velopment is betrixaban. not only has betrixaban 
demonstrated anti-clotting activity in venous throm-
boembolism prevention trials in total knee replace-
ment surgery patients, and showed promises for stroke 
prevention in atrial fibrillation, but is the only novel 
oral anti-clotting agent being tested in patients with 
renal malfunction. 
Corticosteroids and other immunosuppressant 
therapies, such as azathioprine, cyclophosphamide 
and methotrexate, and rituximab (monoclonal anti-
body) have been reported in some studies to decrease 
the titers of lupus anticoagulant and anticardiolipin 
antibodies, but do not seem to decrease thrombotic 
risk. because of the high anticardiolipin antibody titer 
in our patient, we administered corticosteroids hoping 
to reduce the chance for thrombosis recurrence, but 
corticosteroids may have been the precipitating fac-
tor of cutaneous infection and concomitant superfi-
cial thrombophlebitis in our patient. The critical areas 
for future research include identification of patients 
with antiphospholipid antibodies that are at the high-
est risk of thrombotic complications, developing new 
antithrombotic agents that are efficacious and safe, 
and investigating novel approaches to eliminate the 
autoantibody and, hopefully, the increased prothrom-
botic state.
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sažetak
ReCidivi vensKe tRomboZe unAtoČ “optimAlne AntiKoAgulAntne teRApiJe” 
Antifosfolipidnog sindRomA. mogu li novi peRoRAlni AntiKoAgulAnsi RiJeŠiti 
pRoblem? 
M. Balaban, V. Stančić, G. Rinčić, M. Ledinsky, Lj. Grbac, N. Stančić i h. tomašić
Cilj je bio analizirati uzroke neuspjeha “optimalno doziranog” varfarina kod prevencije recidiva duboke venske trom-
boze u bolesnika s antifosfolipidnim sindromom. opisuje se slučaj 63-godišnje bolesnice s antifosfolipidnim sindromom i 
recidivima venske tromboze tijekom uzimanja varfarina. vrijednosti inR bile su u terapijskim granicama. Analizirali su 
se patofiziološki mehanizmi nastanka tromboze i literaturni podaci. Rezultati su pokazali kako u bolesnika s pozitivnim 
lupus antikoagulans (lA) testom vrijednost pv-inR ne daje pravu sliku protuzgrušavajućeg učinka varfarina. Aktivnost 
pv je zbog interferencije često lažno smanjena, iako u času mjerenja bolesnik ne uzima varfarin ili drugi antagonist vita-
mina K. Zaključak je kako prisutnost lA može interferencijom lažno smanjiti aktivnost u pv testu i rezultirati nalazom 
inR koji ne odražava pravo stanje protuzgrušavajuće aktivnosti izazvane varfarinom. u tom bi slučaju umjesto pv testa 
trebalo mjeriti aktivnost faktora Xa kromogenom metodom koja je neosjetljiva na lA. drugo moguće rješenje bi u bole-
snika s antifosfolipidnim sindromom bila zamjena varfarina novim lijekovima, oralnim inhibitorima trombina i faktora X. 
ovi lijekovi u fiksnoj dozi s predvidivim te o hrani i lijekovima uglavnom neovisnim protuzgrušavajućim učinkom imaju 
djelotvornost i nuspojave uglavnom slične varfarinu, ali ne trebaju kontrole inR.
Ključne riječi: Antifosfolipidni sindrom – komplikacije; Antifosfolipidni sindrom – terapija lijekovima; Tromboza – etiologija; 
Tromboza – prevencija i kontrola; Varfarin – terapijska primjena; Prikaz slučaja

